Evidence map›Paper›PMID 20084112›Full record

ArticlePLoS pathogens2010

Marburg virus evades interferon responses by a mechanism distinct from ebola virus.

Charalampos Valmas, Melanie N Grosch, Michael Schümann, Judith Olejnik, Osvaldo Martinez, Sonja M Best, Verena Krähling, Christopher F Basler, Elke Mühlberger

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 179 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Marburg Virus Disease: A Narrative Review.Health science reports · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Molecular determinants of cross-species transmission in emerging viral infections.Microbiology and molecular biology reviews : MMBR · 2024
    Review
  10. Article
  11. Review
  12. Reverse Genetics Systems for Filoviruses.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Charalampos ValmasDepartment of Microbiology, Mount Sinai School of Medicine, New York, New York, USA.
Melanie N Grosch
Michael Schümann
Judith Olejnik
Osvaldo Martinez
Sonja M Best
Verena Krähling
Christopher F Basler
Elke Mühlberger
Philipps University of Marburg · DEIcahn School of Medicine at Mount Sinai · USBoston University · USNational Institutes of Health · US

Funding

Viral Pathogenesis and TherapeuticsU54AI057158 · NIAID · WADSWORTH CENTER · PI LEVY, DAVID E · 2003 to 2014
$100.8M
Virus-Host Interactions: Induction and Evasion of Host Innate ImmunityZIAAI001125 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BEST, SONJA · 2010 to 2025
$28.1M
Ebola VP35 Interferon-Antagonist: Mechanism and SignifR01AI059536 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BASLER, CHRISTOPHER F · 2005 to 2015
$4.2M
Early Host Immune Response in Protection Against Filovirus InfectionU01AI082954 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MUHLBERGER, ELKE C · 2009 to 2013
$3.3M
Intramural NIH HHSNIAID NIH HHS AI057158NIAID NIH HHS AI059536NIAID NIH HHS R01 AI059536NIAID NIH HHS U01 AI082954NIAID NIH HHS U54 AI057158
6 · The paper itself

Abstract

Previous studies have demonstrated that Marburg viruses (MARV) and Ebola viruses (EBOV) inhibit interferon (IFN)-alpha/beta signaling but utilize different mechanisms. EBOV inhibits IFN signaling via its VP24 protein which blocks the nuclear accumulation of tyrosine phosphorylated STAT1. In contrast, MARV infection inhibits IFNalpha/beta induced tyrosine phosphorylation of STAT1 and STAT2. MARV infection is now demonstrated to inhibit not only IFNalpha/beta but also IFNgamma-induced STAT phosphorylation and to inhibit the IFNalpha/beta and IFNgamma-induced tyrosine phosphorylation of upstream Janus (Jak) family kinases. Surprisingly, the MARV matrix protein VP40, not the MARV VP24 protein, has been identified to antagonize Jak and STAT tyrosine phosphorylation, to inhibit IFNalpha/beta or IFNgamma-induced gene expression and to inhibit the induction of an antiviral state by IFNalpha/beta. Global loss of STAT and Jak tyrosine phosphorylation in response to both IFNalpha/beta and IFNgamma is reminiscent of the phenotype seen in Jak1-null cells. Consistent with this model, MARV infection and MARV VP40 expression also inhibit the Jak1-dependent, IL-6-induced tyrosine phosphorylation of STAT1 and STAT3. Finally, expression of MARV VP40 is able to prevent the tyrosine phosphorylation of Jak1, STAT1, STAT2 or STAT3 which occurs following over-expression of the Jak1 kinase. In contrast, MARV VP40 does not detectably inhibit the tyrosine phosphorylation of STAT2 or Tyk2 when Tyk2 is over-expressed. Mutation of the VP40 late domain, essential for efficient VP40 budding, has no detectable impact on inhibition of IFN signaling. This study shows that MARV inhibits IFN signaling by a mechanism different from that employed by the related EBOV. It identifies a novel function for the MARV VP40 protein and suggests that MARV may globally inhibit Jak1-dependent cytokine signaling.

Indexed as

AnimalsBlotting, WesternCell LineCytokinesEbolavirusEnzyme-Linked Immunosorbent AssayFluorescent Antibody TechniqueHemorrhagic Fever, EbolaHumansImmune EvasionInterferonsJanus Kinase 1MarburgvirusMarburg Virus DiseasePolymerase Chain ReactionSignal TransductionCytokinesInterferonsJanus Kinase 1Viral Matrix ProteinsVP40 protein, virus

Identifiers

PMID20084112
PMCPMC2799553
OpenAlexW2076028337

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.